First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohort expansion portion (1B).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażenie świadomej zgody na udział w badaniu.
- •Pacjenci w wieku 18 lat lub starsi.
- •Potwierdzone badaniami, że choroba nowotworowa jest zaawansowana.
- •Obecność co najmniej jednej zmiany nowotworowej widocznej w badaniach obrazowych.
- •Pacjenci z nawracającymi lub opornymi na leczenie nowotworami, którzy wyczerpali inne opcje.
- •Pacjenci, u których ostatnie leczenie (chemioterapia, radioterapia) zakończyło się co najmniej 4 tygodnie wcześniej.
- •Dobry ogólny stan zdrowia (oceniany według skali ECOG ≤ 2).
- •Wystarczająca ilość prawidłowych komórek krwi oraz prawidłowe wyniki badań wątroby i nerek.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 28, 2022
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, United States
Trial contact
Ginette Serrero, PhD/DSC.
Katherine Tkaczuk, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.